Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.3438
Abstract: GLPG3970 is a selective salt‐inducible kinase 2/3 inhibitor intended for the treatment of inflammatory diseases. In vitro studies suggest GLPG3970 strongly inhibits breast cancer resistance protein (BCRP), indicating a possible interaction with BCRP substrates such… read more here.
Keywords: ssz; bcrp; glpg3970; drug ... See more keywords